OB:ABT

Stock Analysis Report

Aqua Bio Technology

Executive Summary

Aqua Bio Technology ASA engages in developing and commercializing active ingredients for use in skin care products in Norway.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Risks

  • Aqua Bio Technology is not covered by any analysts.

Share Price & News

How has Aqua Bio Technology's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

ABT

-1.5%

NO Chemicals

1.9%

NO Market


1 Year Return

-39.4%

ABT

-8.9%

NO Chemicals

-8.5%

NO Market

ABT underperformed the Chemicals industry which returned -8.9% over the past year.

ABT underperformed the Market in Norway which returned -8.5% over the past year.


Share holder returns

ABTIndustryMarket
7 Day0%-1.5%1.9%
30 Day0%5.8%8.2%
90 Day-13.2%-0.2%3.4%
1 Year-39.4%-39.4%-5.3%-8.9%-3.5%-8.5%
3 Year-75.1%-79.5%24.6%13.5%50.1%30.5%
5 Year-79.1%-85.4%46.4%25.1%53.2%17.1%

Price Volatility Vs. Market

How volatile is Aqua Bio Technology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aqua Bio Technology undervalued based on future cash flows and its price relative to the stock market?

1.09x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Aqua Bio Technology to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Aqua Bio Technology to establish if it is available at substantial discount.


Price Based on Earnings

Aqua Bio Technology is loss making, we can't compare its value to the Europe Chemicals industry average.

Aqua Bio Technology is loss making, we can't compare the value of its earnings to the Norway market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Aqua Bio Technology, we can't assess if its growth is good value.


Price Based on Value of Assets

Aqua Bio Technology is good value based on assets compared to the Europe Chemicals industry average.


Next Steps

Future Growth

How is Aqua Bio Technology expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

6.8%

Forecasted Materials industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aqua Bio Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Aqua Bio Technology performed over the past 5 years?

-57.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Aqua Bio Technology does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Aqua Bio Technology's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Aqua Bio Technology's 1-year growth to the Europe Chemicals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Aqua Bio Technology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Aqua Bio Technology has efficiently used its assets last year compared to the Europe Chemicals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Aqua Bio Technology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Aqua Bio Technology's financial position?


Financial Position Analysis

Aqua Bio Technology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Aqua Bio Technology has no long term commitments.


Debt to Equity History and Analysis

Aqua Bio Technology has no debt.

Aqua Bio Technology has no debt compared to 5 years ago when it was 11.9%.


Balance Sheet

High level of physical assets or inventory.

Aqua Bio Technology has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Aqua Bio Technology has less than a year of cash runway based on current free cash flow.

Aqua Bio Technology has less than a year of cash runway if free cash flow continues to grow at historical rates of 103.9% each year.


Next Steps

Dividend

What is Aqua Bio Technology's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Aqua Bio Technology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Aqua Bio Technology's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Aqua Bio Technology has not reported any payouts.

Unable to verify if Aqua Bio Technology's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Aqua Bio Technology has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Aqua Bio Technology's salary, the management and board of directors tenure and is there insider trading?

2.7yrs

Average board tenure


CEO

Espen Kvale (41yo)

0.8yrs

Tenure

0

Mr. Espen Østhagen Kvale serves as an Interim Chief Executive Officer at Aqua Bio Technology ASA since December 2018. He served as Consultant of Aqua Bio Technology ASA until December 2018 and served as it ...


CEO Compensation Analysis

Espen's remuneration is lower than average for companies of similar size in Norway.

Espen's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

2.7yrs

Average Tenure

57yo

Average Age

The average tenure for the Aqua Bio Technology board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Arvid Lindberg (45yo)

    Head of Sales & Marketing

    • Tenure: 0.8yrs
    • Compensation: kr2.23m
  • Hans Leren

    Chief Technology Officer

    • Tenure: 0yrs
  • Espen Kvale (41yo)

    Interim Chief Executive Officer

    • Tenure: 0.8yrs

Board Members

  • Tone Bjørnov (58yo)

    Director

    • Tenure: 11.2yrs
    • Compensation: kr145.00k
  • Roger Hofseth (45yo)

    Director

    • Tenure: 0.7yrs
  • Edvard Cock (49yo)

    Chairman of the Board

    • Tenure: 0yrs
    • Compensation: kr285.00k
  • Kristian Aase (57yo)

    Director

    • Tenure: 2.7yrs
    • Compensation: kr145.00k
  • Jan Hakan Pettersson (61yo)

    Director

    • Tenure: 0yrs
    • Compensation: kr145.00k

Company Information

Aqua Bio Technology ASA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aqua Bio Technology ASA
  • Ticker: ABT
  • Exchange: OB
  • Founded: 2000
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: kr32.227m
  • Shares outstanding: 15.35m
  • Website: https://www.aquabiotechnology.com

Location

  • Aqua Bio Technology ASA
  • Fornebuveien 37
  • Lysaker
  • Akershus
  • 1366
  • Norway

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ABTOB (Oslo Bors)YesOrdinary SharesNONOKJan 2008

Biography

Aqua Bio Technology ASA engages in developing and commercializing active ingredients for use in skin care products in Norway. It offers Aquabeautine XL, a proprietary ingredient; and Spirulysat, an antioxi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 21:07
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.